Controlled release of vascular endothelial growth factor from spray-dried alginate microparticles in collagen–hydroxyapatite scaffolds for promoting vascularization and bone repair

Journal of Tissue Engineering and Regenerative Medicine

Volumn 11, Issue 4, 2017, Pages 1097-1109

  Quinlan, Elaine ^a,b   López Noriega, Adolfo ^a,b   Thompson, Emmet M ^a,b   Hibbitts, Alan ^a,b   Cryan, Sally Ann ^a,b   O'Brien, Fergal J ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

angiogenesis; collagen scaffolds; osteogenesis; polymeric alginate microparticles; spray drying; tissue engineering; vascular endothelial growth factor

Indexed keywords

ALGINATE; BONE; CELL ENGINEERING; COLLAGEN; COPYRIGHTS; DEFECTS; ENDOTHELIAL CELLS; HYDROXYAPATITE; SCAFFOLDS (BIOLOGY); SPRAY DRYING;

ALGINATE MICROPARTICLES; ANGIOGENESIS; BONE REGENERATION; COLLAGEN SCAFFOLDS; FUNCTIONALIZED; OSTEOGENESIS; POLYMERIC ALGINATE MICROPARTICLE; SPRAY-DRYING; TISSUES ENGINEERINGS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

TISSUE REGENERATION;

ALGINIC ACID; COLLAGEN HYDROXYAPATITE SCAFFOLD; MOLECULAR SCAFFOLD; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOMATERIAL; COLLAGEN; GLUCURONIC ACID; HEXURONIC ACID; HYDROXYAPATITE; MICROSPHERE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BONE REGENERATION; BONE REMODELING; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; ENDOTHELIUM CELL; FREEZE DRYING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; RAT; SPRAY DRYING; VASCULARIZATION; ANIMAL; BONE DEVELOPMENT; CHEMISTRY; CYTOLOGY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; MALE; MICRO-COMPUTED TOMOGRAPHY; PHARMACOLOGY; POROSITY; TISSUE SCAFFOLD; UMBILICAL VEIN ENDOTHELIAL CELL; WISTAR RAT;

ALGINATES; ANIMALS; BIOCOMPATIBLE MATERIALS; BONE REGENERATION; COLLAGEN; DELAYED-ACTION PREPARATIONS; DURAPATITE; GLUCURONIC ACID; HEXURONIC ACIDS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; MALE; MICROSPHERES; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOGENESIS; POROSITY; RATS, WISTAR; TISSUE SCAFFOLDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; X-RAY MICROTOMOGRAPHY;

EID: 85017199633     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.2013     Document Type: Article

References (57)

1. Abramoff MD, Magelhaes PJ, Ram SJ et al. 2004; Image processing with Image. J Biophoton Int 11(7): 36–42.
2. Borselli C, Ungaro F, Oliviero O et al. 2010; Bioactivation of collagen matrices through sustained VEGF release from PLGA microspheres. J Biomed Mater Res A 92(1): 94–102.
3. Bowey K, Swift BE, Flynn LE et al. 2013; Characterization of biologically active insulin-loaded alginate microparticles prepared by spray drying. Drug Dev Ind Pharm 39(3): 457–465.
4. Buttafoco L, Engbers-Buijtenhuijs P, Poot AA et al. 2006; First steps towards tissue engineering of small-diameter blood vessels: preparation of flat scaffolds of collagen and elastin by means of freeze drying. J Biomed Mater Res B Appl Biomater 77(2): 357–368.
5. Byrne EM, Farrell E, McMahon LA et al. 2008; Gene expression by marrow stromal cells in a porous collagen–glycosaminoglycan scaffold is affected by pore size and mechanical stimulation. J Mater Sci Mater Med 19(11): 3455–3463.
6. Chen RR, Mooney DJ. 2003; Polymeric growth factor delivery strategies for tissue engineering. Pharm Res 20(8): 1103–1112.
7. Clarke SA, Hoskins NL, Jordan GR et al. 2007; Healing of an ulnar defect using a proprietary TCP bone graft substitute, JAX, in association with autologous osteogenic cells and growth factors. Bone 40(4): 939–947.
8. Cunniffe GM, Dickson GR, Partap S et al. 2010; Development and characterisation of a collagen–nano-hydroxyapatite composite scaffold for bone tissue engineering. J Mater Sci Mater Med 21(8): 2293–2298.
9. De Franceschi L, Grigolo B, Roseti L et al. 2005; Transplantation of chondrocytes seeded on collagen-based scaffold in cartilage defects in rabbits. J Biomed Mater Res A 75(3): 612–622.
10. Epstein NE. 2011; Pros, cons, and costs of INFUSE in spinal surgery. Surg Neurol Int 2: 10.
11. Geiger F, Bertram H, Berger I et al. 2005; Vascular endothelial growth factor gene-activated matrix (VEGF165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J Bone Miner Res 20(11): 2028–2035.
12. George M, Abraham TE. 2006; Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan – a review. J Control Release 114(1): 1–14.
13. Gleeson JP, Plunkett NA, O'Brien FJ et al. 2010; Addition of hydroxyapatite improves stiffness, interconnectivity and osteogenic potential of a highly porous collagen-based scaffold for bone tissue regeneration. Eur Cell Mater 20: 218–230.
14. Griffith M, Jackson WB, Lagali N et al. 2009; Artificial corneas: a regenerative medicine approach. Eye (Lond) 23(10): 1985–1989.
15. Hascicek C, Gonul N, Erk N et al. 2003; Mucoadhesive microspheres containing gentamicin sulfate for nasal administration: preparation and in vitro characterization. Farmaco 58(1): 11–16.
16. Haugh MG, Murphy CM, O'Brien FJ et al. 2010; Novel freeze-drying methods to produce a range of collagen–glycosaminoglycan scaffolds with tailored mean pore sizes. Tissue Eng C Methods 16(5): 887–894.
17. Hulbert SF, Young FA, Mathews RS et al. 1970; Potential of ceramic materials as permanently implantable skeletal prostheses. J Biomed Mater Res 4(3): 433–456.
18. I Ré M. 1998; Microencapsulation by spray drying. Drying Technol 16(6): 1195–1236.
19. Kaigler D, Wang Z, Horger K et al. 2006; VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. J Bone Miner Res 21(5): 735–744.
20. Keogh MB, Fj OB, Daly JS et al. 2010; A novel collagen scaffold supports human osteogenesis – applications for bone tissue engineering. Cell Tissue Res 340(1): 169–177.
21. Kubota Y, Kleinman HK, Martin GR et al. 1988; Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 107(4): 1589–1598.
22. Langer R. 1998; Drug delivery and targeting. Nature 392(suppl 6679): 5–10.
23. Lee J, Lee KY. 2009; Local and sustained vascular endothelial growth factor delivery for angiogenesis using an injectable system. Pharm Res 26(7): 1739–1744.
24. Lee KY, Mooney DJ. 2012; Alginate: properties and biomedical applications. Prog Polym Sci 37(1): 106–126.
25. Lieberman JR, Daluiski A, Einhorn TA et al. 2002; The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 84A(6): 1032–1044.
26. Lu CH, Chang YH, Lin SY et al. 2013; Recent progresses in gene delivery-based bone tissue engineering. Biotechnol Adv 31(8): 1695–1706.
27. Lyons FG, Al-Munajjed AA, Kieran SM et al. 2010; The healing of bony defects by cell-free collagen-based scaffolds compared to stem cell-seeded tissue engineered constructs. Biomaterials 31(35): 9232–9243.
28. Lyons FG, Gleeson JP, Partap S et al. 2014; Novel microhydroxyapatite particles in a collagen scaffold: a bioactive bone void filler? Clin Orthop Rel Res 1–11.
29. Marino JT, Ziran BH. 2010; Use of solid and cancellous autologous bone graft for fractures and nonunions. Orthop Clin N Am 41(1): 15–26.
30. Mayr-Wohlfart U, Waltenberger J, Hausser H et al. 2002; Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 30(3): 472–477.
31. McCoy RJ, Widaa A, Watters KM et al. 2013; Orchestrating osteogenic differentiation of mesenchymal stem cells – identification of placental growth factor as a mechanosensitive gene with a pro-osteogenic role. Stem Cells 31(11): 2420–2431.
32. Murphy CM, O'Brien FJ. 2010; Understanding the effect of mean pore size on cell activity in collagen–glycosaminoglycan scaffolds. Cell Adh Migr 4(3): 377–381.
33. Norrby K, Ridell B. 2003; Tumour type-specific capillary endothelial cell stainability in malignant B cell lymphomas using antibodies against CD31, CD34 and factor VIII. Acta Pathol Microbiol Immunol Scand 111(4): 483–489.
34. Novosel EC, Kleinhans C, Kluger PJ et al. 2011; Vascularization is the key challenge in tissue engineering. Adv Drug Deliv Rev 63(4–5): 300–311.
35. O'Brien FJ, Gleeson J, Plunkett N. 2008; A collagen–hydroxyapatite composite scaffold, and process for the production thereof. R Coll Surg Ireland WO/2008/096334.
36. O'Brien FJ, Harley BA, Yannas IV et al. 2005; The effect of pore size on cell adhesion in collagen–GAG scaffolds. Biomaterials 26(4): 433–441.
37. O'Brien FJ, Lopez-Noriega A, Quinlan E, et al. 2012; A composite scaffold for use as a tissue engineering implant. R Coll Surg Ireland P10963GB00.
38. Patel ZS, Young S, Tabata Y et al. 2008; Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone 43(5): 931–940.
39. Peters MC, Isenberg BC, Rowley JA et al. 1998; Release from alginate enhances the biological activity of vascular endothelial growth factor. J Biomater Sci Polym Ed 9(12): 1267–1278.
40. Pufe T, Wildemann B, Petersen W et al. 2002; Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing: a study in the rat. Cell Tissue Res 309(3): 387–392.
41. Quinlan E, Lopez-Noriega A, Thompson E et al. 2015; Development of collagen-hydroxyapatite scaffolds incorporating PLGA and alginate microparticles for the controlled delivery of rhBMP-2 for bone tissue engineering. J Control Release 198: 71–79.
42. Reis CP, Neufeld RJ, Vilela S et al. 2006; Review and current status of emulsion/dispersion technology using an internal gelation process for the design of alginate particles. J Microencapsul 23(3): 245–257.
43. Richardson TP, Peters MC, Ennett AB et al. 2001; Polymeric system for dual growth factor delivery. Nat Biotechnol 19(11): 1029–1034.
44. Schoubben A, Blasi P, Giovagnoli S et al. 2010; Development of a scalable procedure for fine calcium alginate particle preparation. Chem Eng J 160(1): 363–369.
45. Silva EA, Mooney DJ. 2010; Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 31(6): 1235–1241.
46. Sivadas N, O'Rourke D, Tobin A et al. 2008; A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm 358(1–2): 159–167.
47. Stacker SA, Achen MG. 1999; The vascular endothelial growth factor family: signalling for vascular development. Growth Factors 17(1): 1–11.
48. Street J, Bao M, de Guzman L et al. 2002; Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 99(15): 9656–9661.
49. Suehiro J, Hamakubo T, Kodama T et al. 2010; Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3. Blood 115(12): 2520–2532.
50. Swetha M, Sahithi K, Moorthi A et al. 2010; Biocomposites containing natural polymers and hydroxyapatite for bone tissue engineering. Int J Biol Macromol 47(1): 1–4.
51. Tsiridis E, Upadhyay N, Giannoudis P et al. 2007; Molecular aspects of fracture healing: which are the important molecules? Injury 38(suppl 1): S11–25.
52. Vehring R. 2008; Pharmaceutical particle engineering via spray drying. Pharm Res 25(5): 999–1022.
53. Wahl DA, Czernuszka JT. 2006; Collagen-hydroxyapatite composites for hard tissue repair. Eur Cell Mater 11: 43–56.
54. Weadock KS, Miller EJ, Bellincampi LD et al. 1995; Physical crosslinking of collagen fibers: comparison of ultraviolet irradiation and dehydrothermal treatment. J Biomed Mater Res 29(11): 1373–1379.
55. Weadock KS, Miller EJ, Keuffel EL et al. 1996; Effect of physical crosslinking methods on collagen fiber durability in proteolytic solutions. J Biomed Mater Res 32(2): 221–226.
56. Wernike E, Montjovent MO, Liu Y et al. 2010; VEGF incorporated into calcium phosphate ceramics promotes vascularisation and bone formation in vivo. Eur Cell Mater 19: 30–40.
57. Zocchi MR, Ferrero E, Leone BE et al. 1996; CD31/PECAM-1-driven chemokine-independent transmigration of human T lymphocytes. Eur J Immunol 26(4): 759–767.